Short answer
Insulet Corporation (PODD) filed its fiscal 2025 10-K annual report with the SEC on Feb 18, 2026. It reported revenue of $2.7B (+30.7% year over year) and net income of $247M.
- Top risk flagged: Cybersecurity risk oversight primarily by NGR Committee with regular updates from CISO and strategic roadmap reviews
FY2025 key financial metrics · XBRL
- Revenue
- $2.7B
- +30.7% YoY
- Net income
- $247M
- −40.9% YoY
- Operating margin
- 17.5%
- +2.6 pp YoY
- Gross margin
- 71.6%
- +1.8 pp YoY
- EPS (diluted)
- $3.48
- −39.8% YoY
- ROE
- 16.3%
- −18.2 pp YoY
- Operating cash flow
- $569M
- +32.3% YoY
Source: XBRL data from the Insulet Corporation (PODD) FY2025 10-K on SEC EDGAR. USD.
Insulet Corporation FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business in marketing and product training within healthcare, focusing on compliance with complex healthcare laws like Medicare, Medicaid, and anti-bribery statutes
- Emphasis on advanced AI tool deployment and adherence to evolving global privacy, data protection, and AI regulations including EU AI Act by August 2026
- Strategic focus on managing cybersecurity risks and potential data breaches amid increased reliance on cloud-hosted systems and AI infrastructure
- Notable leadership changes in 2025 including new CEO and CFO, impacting talent retention and operational continuity
- Elevated regulatory and compliance risks due to expanded data privacy laws (e.g., CCPA, CPRA), complex IT security challenges, and credit agreement restrictions affecting capital flexibility
Management Discussion & Analysis
- Revenue $2,708.1M in 2025, up 30.7% YoY (+$636.6M); U.S. revenue $1,919.8M (+27.2%), International $754.3M (+44.1%)
- Gross margin 71.6% in 2025 vs 69.8% in 2024; R&D expense 11.1% of revenue vs 10.6%; SG&A 43.0% vs 44.3%
- Best segment: International Omnipod Products up $230.9M (44.1%); worst: Drug Delivery down 12.3% or $4.8M to $34.1M
- Free cash flow $377.7M, up $72.4M; Capex $191.6M (+53%), share repurchase $59.6M in 2025, $300M planned in Q1 2026
- 2026 outlook: Expected strong U.S. and International revenue growth from recurring sales and Omnipod 5 adoption; tariff risk if medical device exemptions eliminated
Risk Factors
- Cybersecurity risk oversight primarily by NGR Committee with regular updates from CISO and strategic roadmap reviews
- CISO reports to CTO, leading cybersecurity program including risk detection and continuous improvement in medical device manufacturing
- CTO with 15+ years experience co-chairs Technology Risk Committee ensuring cybersecurity governance and remediation actions
- No specific regulatory, geopolitical, operational, competitive, or financial risks detailed beyond cybersecurity governance
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.